Pipeline

Focused lead. Preserved optionality.

UL-01 is Telesti’s lead corporate program. A chemically and developmentally distinct backup strategy is intended to preserve option value without diffusing execution.

LeadSmall molecule

UL-01

Lead preclinical program designed to evaluate a differentiated neuroplasticity profile with reduced perceptual and operational limitations.

Current stage · Preclinical lead optimization

Evaluation spans functional serotonergic pharmacology, neuroplasticity, CNS exposure, translational evidence, integrated cardiovascular risk and candidate-specific CMC.

Next objective checkpoint

Development-candidate nomination and a distinct backup supported by a disciplined regulatory plan.

DiscoveryHit IDLead opt.PreclinicalIND-enabling

Backup strategyDiscovery

Distinct backup series

A chemically and developmentally distinct series intended to protect the program from lead-specific pharmacology, exposure, safety, manufacturing or IP risk.

Current stage · Discovery

The backup must preserve genuine option value rather than reproduce the lead’s dominant liability.

Next objective checkpoint

Lead-selection criteria and documented differentiation from UL-01.

DiscoveryHit IDLead opt.PreclinicalIND-enabling

Claims boundary

What the current stage does—and does not—mean.

Preclinical optimization means the company is testing whether the integrated profile supports candidate nomination. It does not mean safety, efficacy, human perceptual differentiation, IND readiness or regulatory approval has been established.

Public pipeline discipline
Telesti does not publish confidential structures, exact candidate thresholds, interim data, speculative program dates or conditional partnership programs before written status and formal approval.

Partnerships

Discuss scientific or strategic fit.

Controlled technical materials are provided through an appropriate diligence process.

Discuss a partnership